U.S. Markets closed

Teva says confident in FY13 guidance provied on November 30

Says committed to returning cash to shareholders. Says launched 23 generic products in 2012, expects to launch a similar number of products in 2013. Sees FY13 expenses more front-loaded. The company clarified that it is fully committed to the generic injectables business.